Shares of NextBioMedical are showing strong gains of over 9% following news of the company’s entry into the Japanese market.

[Market Focus] NextBioMedical Soars 9% on News of 'Nexphere-F' Entry into Japan View original image

As of 9:19 a.m. on April 10, 2026, NextBioMedical was trading at 66,300 won, up 5,500 won (9.05%) from the previous trading day.


On this day, NextBioMedical announced that it had signed a licensing agreement with Asahi Intecc, a global medical device company based in Japan, for the Japanese distribution rights of Nexphere-F, a vascular embolization-promoting prosthesis. Asahi Intecc is a specialized medical device company with a strong presence in global markets, including the United States, Europe, China, and India.


This contract was executed in the form of supplying finished products. Nexphere-F, the vascular embolization-promoting prosthesis, has received product approvals from the Ministry of Food and Drug Safety in Korea, the European Medical Device Directive (CE-MDD), and Health Canada. Post-marketing clinical trials are currently underway both domestically and internationally. Clinical trials for approval by the U.S. Food and Drug Administration (FDA) are also ongoing, with the goal of obtaining FDA approval.



Asahi Intecc plans to conduct clinical trials for Japanese PMDA approval of Nexphere-F, targeting patients suffering from certain chronic pain conditions.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing